Humanigen Raises Chances of Lenzilumab EUA With Severe COVID-19 Data
Data on medRxiv showed a 90% improvement in likelihood of need for mechanical ventilation in the intent-to-treat population. The company plans a filing in Q2.
You may also be interested in...
Phase III results show benefit in cytokine-release syndrome, while other drugs for treating patients hospitalized with COVID-19 have produced mixed results.
With elderly patients disproportionately facing hospitalization and death from COVID-19, success in the clinic would create an important market for the drug.
Roche's Actemra is a major player in this space, but Humanigen is looking to take it on directly.